Atara Biotherapeutics Inc.

Last updated September 27, 2026
Favorite this organization

Organization details

Legal name
Atara Biotherapeutics Inc.
Ownership
Public
Status
Active
SIC code
2836 — Biological Products, (No Diagnostic Substances)
Jurisdiction of incorporation
Delaware
Headquarters city
Thousand Oaks
Headquarters state / province
California
Headquarters country
United States
Fiscal year end
December
Ticker symbol
ATRA
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001604464
EIN
46-0920988

Board of directors

Follow this board

Chief executives

Pascal Touchon · President and CEO
Dates unknown
AnhCo Nguyen · President and CEO
Dates unknown

Director election results

Annual meeting of June 10, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

10 of this board's directors also sit on 22 other boards.

Network of Atara Biotherapeutics Inc.'s board connections Zymeworks Inc. Zymeworks Inc. ADC Therapeutics SA ADC Therapeutics SA Absci Corporation Absci Corporation Alaunos Therapeutics Inc. Alaunos Therapeutics I... Connect Biopharma Holdings Limited Connect Biopharma Hold... Electra Therapeutics Inc. Electra Therapeutics I... Fate Therapeutics Inc. Fate Therapeutics Inc. Gossamer Bio Inc. Gossamer Bio Inc. Jade Biosciences Inc. Jade Biosciences Inc. Janux Therapeutics Inc. Janux Therapeutics Inc... Kyverna Therapeutics Inc. Kyverna Therapeutics I... Latigo Biotherapeutics Inc. Latigo Biotherapeutics... MacroGenics Inc. MacroGenics Inc. Neumora Therapeutics Inc. Neumora Therapeutics I... PMV Pharmaceuticals Inc. PMV Pharmaceuticals In... Progyny Inc. Progyny Inc. Ameet Mallik Ameet Mallik Beth C. Seidenberg Beth C. Seidenberg Brian N. Cherry Brian N. Cherry Carol Giltner Gallagher Carol Giltner Gallag... Eric Dobmeier Eric Dobmeier Gregory Austin Ciongoli Gregory Austin Ciong... James Huang James Huang Jeremy Green Jeremy Green Matthew K. Fust Matthew K. Fust William K. Heiden William K. Heiden Atara Biotherapeutics Inc.
Shared director Other board Same sector +6 more in the list below

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$5,744,249
2 purchases by 2 insiders
Sold, last 12 months
$3,853,719
18 sales by 3 insiders
Date Insider Transaction Shares Price Value
Sep 4, 2026 Brian N. Cherry Director Open-market purchase +104,166 $9.60 $999,994
Aug 17, 2026 AnhCo Nguyen Director, Officer (President and CEO) Open-market sale −5,062 $8.08 $40,883
Jul 22, 2026 Redmile Group, LLC Director Option exercise +195,211 — —
Jul 22, 2026 Redmile Group, LLC Director Shares withheld for tax −60 — —
Jun 11, 2026 Brian N. Cherry Director Grant or award +24,000 — —
Jun 9, 2026 William K. Heiden Director Grant or award +12,000 — —
Jun 9, 2026 Matthew K. Fust Director Grant or award +12,000 — —
Jun 9, 2026 Gregory Austin Ciongoli Director, 10% owner, See Remarks Grant or award +12,000 — —
May 18, 2026 AnhCo Nguyen Director, Officer (President and CEO) Open-market sale −5,241 $9.13 $47,850
May 18, 2026 Grant-Huerta Yanina Officer (Chief Accounting Officer) Open-market sale −2,414 $9.13 $22,040
May 7, 2026 James Huang Director, 10% owner Open-market sale −313,446 $10.10 $3,165,805
May 7, 2026 EcoR1 Capital, LLC 10% owner Open-market purchase +507,407 $9.35 $4,744,255
Mar 17, 2026 James Huang Director, 10% owner Option exercise +259,163 — —
Mar 17, 2026 James Huang Director, 10% owner Shares withheld for tax −5 $5.23 $26
Mar 9, 2026 AnhCo Nguyen Director, Officer (President and CEO) Grant or award +81,100 — —

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.